JP2024526835A5 - - Google Patents

Info

Publication number
JP2024526835A5
JP2024526835A5 JP2024503351A JP2024503351A JP2024526835A5 JP 2024526835 A5 JP2024526835 A5 JP 2024526835A5 JP 2024503351 A JP2024503351 A JP 2024503351A JP 2024503351 A JP2024503351 A JP 2024503351A JP 2024526835 A5 JP2024526835 A5 JP 2024526835A5
Authority
JP
Japan
Application number
JP2024503351A
Other languages
Japanese (ja)
Other versions
JP2024526835A (ja
JPWO2023004304A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/073877 external-priority patent/WO2023004304A1/en
Publication of JP2024526835A publication Critical patent/JP2024526835A/ja
Publication of JP2024526835A5 publication Critical patent/JP2024526835A5/ja
Publication of JPWO2023004304A5 publication Critical patent/JPWO2023004304A5/ja
Pending legal-status Critical Current

Links

JP2024503351A 2021-07-20 2022-07-19 Cd8結合ポリペプチド及びその使用 Pending JP2024526835A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163223786P 2021-07-20 2021-07-20
US63/223,786 2021-07-20
US202163288111P 2021-12-10 2021-12-10
US63/288,111 2021-12-10
PCT/US2022/073877 WO2023004304A1 (en) 2021-07-20 2022-07-19 Cd8-binding polypeptides and uses thereof

Publications (3)

Publication Number Publication Date
JP2024526835A JP2024526835A (ja) 2024-07-19
JP2024526835A5 true JP2024526835A5 (https=) 2025-07-18
JPWO2023004304A5 JPWO2023004304A5 (https=) 2025-07-18

Family

ID=82898944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024503351A Pending JP2024526835A (ja) 2021-07-20 2022-07-19 Cd8結合ポリペプチド及びその使用

Country Status (6)

Country Link
US (1) US20250320295A1 (https=)
EP (1) EP4373854A1 (https=)
JP (1) JP2024526835A (https=)
CA (1) CA3225092A1 (https=)
TW (1) TW202321283A (https=)
WO (1) WO2023004304A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PT1678314E (pt) 2003-10-22 2012-11-27 Keck Graduate Inst Métodos de síntese de polipéptidos heteromultiméricos em levedura utilizando uma estratégia de conjugação haplóide
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
KR20210113265A (ko) * 2019-01-07 2021-09-15 인히브릭스, 인크. 변형된 il-2 폴리펩타이드를 포함하는 폴리펩타이드 및 이의 용도
AU2020287373B2 (en) * 2019-06-05 2026-01-29 Asher Biotherapeutics, Inc. Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
WO2021001289A1 (en) * 2019-07-02 2021-01-07 F. Hoffmann-La Roche Ag Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
WO2021046159A1 (en) * 2019-09-04 2021-03-11 Genentech, Inc. Cd8 binding agents and uses thereof

Similar Documents

Publication Publication Date Title
JP2024526835A5 (https=)
BR102022025291A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
CN307044741S (https=)
CN307047188S (https=)
CN307044589S (https=)
BY13156U (https=)
CN307044189S (https=)
CN307044806S (https=)
BY23982C1 (https=)
CN307046059S (https=)
BY13158U (https=)
BY13176U (https=)
BY13175U (https=)
BY13174U (https=)
CN307046378S (https=)